Fig. 2: Neutralizing activity against pseudotyped viruses and epitope competition of AGP-R mAbs. | npj Viruses

Fig. 2: Neutralizing activity against pseudotyped viruses and epitope competition of AGP-R mAbs.

From: Discovery of potent cross-neutralizing antibodies against Marburg and Ravn viruses with therapeutic potential

Fig. 2

a Neutralizing activities of mAbs were assessed using VSVΔG*MARV-Angola (blue), VSVΔG*MARV-Musoke (orange), VSVΔG*RAVV (gray), and VSVΔG*EBOV (green). Relative infectivity was calculated by setting the infectivity value in the absence of mAbs as 100%. Data represent the mean ± standard errors of three independent experiments. Logistic curves were fitted using nonlinear four-parameter regression and are shown as solid lines. b Competitive binding among mAbs—AGP-R7, -R12, -R17, -R4, -R5, -R11, -R20, MR78, and MR191—was examined using ELISA. AGP-R7, -R12, -R17, -R4, -R5, -R11, -R20, and MR78 were labeled with HRP, and the unlabeled mAbs shown on the right were used as competitors.

Back to article page